Diabetes

The link between low testosterone and decreased insulin sensitivity had been shown in previous research.

Diabetes is a growing epidemic in the United States and new research has indicated that half of healthy 45-year-olds will develop pre-diabetes and one-third will develop diabetes at some point.

The American College of Physicians has published a paper in the Annals of Internal Medicine that advices clinicians to prescribe generic drugs whenever possible.

The policy change is aimed at curbing the state's obesity rate as well as comorbidities such as diabetes

What we're reading, November 25, 2015: UnitedHealthcare's decision on healthcare exchange participation, Democratic Presidential candidate's health plan, and conflict of interest between soda company and anti-obesity research group.

A newly approved therapy offers the first new option in years to prevent hyperkalemia.

What we're reading, November 24, 2015: expensive hepatitis C drugs are more cost effective when used earlier; clinicians aren't prescribing generics enough; and half of health 45-year-olds will develop prediabetes.

Terms of the deal with the second-largest pharmacy benefit manager were not disclosed. Pricing for the PCSK9 inhibitor class has been a source of controversy since the cholesterol-fighting drugs were approved this summer.

Community-based organizations are ideally suited for healthcare prevention efforts and provide a needed linkage to medical care provider systems.

The study credited better drugs and improvements in foot inspections and self-care with the reduction.

John Bel Edwards was elected Governor of Louisiana Saturday after promising to expand Medicaid. Hospitals have been eager to see expansion; in the spring, they supported a fee to pay the state's share once the federal government stops paying 100% of expansion costs.

An Interview with Joslin's George King, MD

The findings suggest that addressing heart patients' social needs is the first step toward getting them to exercise more.

Sequence discovery techniques identified sequences of events that led to gaps in diabetic therapies and were used to identify outreach opportunities aimed at improving medication adherence.

The study population took part in the landmark ORIGIN trial, which evaluated hypoglycemia effects in persons with high CV risk and diabetes.

The action by NICE highlights discussion on both sides of the Atlantic about the cost of PCSK9 inhibitors, which lower LDL cholesterol.

This commentary was adapted from an appearance by the authors at Patient-Centered Diabetes Care, a conference jointly presented by The American Journal of Managed Care and Joslin Diabetes Center.

It is time to regulate laboratory-developed tests that cost Medicare $9.7 billion in the year 2012 alone.

The study suggests treating depression could help combating poor diet and obesity. But in Kentucky, the future of Medicaid expansion is in doubt following the recent election.

Several clinical trials under way are examining whether a new class of therapy approved to treat type 2 diabetes can also treat type 1.

The VEGF inhibitors have been a game-changer in treatment of ocular conditions in diabetes.

A partnership between JDRF and Janssen Pharmaceuticals seeks ways to intercept the disease before it progresses.

Employer policies for access to maximum benefits do not always match those for access to obesity therapy.

Sanofi's vice president of Diabetes Integrated Care discusses the recent collaboration with Google.

St. Peter's Hospital in New Brunswick won the right to a hearing, where New Jersey's largest insurer will have to say why the Catholic hospital was not included in a preferred network set up alongside a major population health initiative.

Results released by Sanofi and Regeneron of their PCSK9 inhibitor were based on prior clinical trials.

The estimated cost per quality-adjusted life year for the PCSK9 drugs is $300,000. How should health plans respond?

Studies at the American Heart Association show very different approaches to exercise for type 2 diabetes patients.

The study presented at the American Heart Association Scientific Session adds to the evidence that SGLT2s are beneficial in treating hypertension.

The study by the well-known health system could not even test some children because they were too large for the MRI machine.